{"analyses":[{"ciLowerLimit":"0.785","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.17","estimateComment":"Cabazitaxel 25 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.958"},{"ciLowerLimit":"0.75","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.118","estimateComment":"Cabazitaxel 20 mg/m\\^2 vs Docetaxel 75 mg/m\\^2","groupDescription":"Hazard ratio was estimated using a Cox Proportional Hazards regression model. The Cox proportional hazard model was adjusted by ECOG PS score at baseline, measurable disease at baseline, and region with commercial availability of cabazitaxel at the time of randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.916"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.30","upperLimit":"13.77","value":"12.1"},{"groupId":"OG001","lowerLimit":"11.37","upperLimit":"14.75","value":"13.4"},{"groupId":"OG002","lowerLimit":"11.66","upperLimit":"14.32","value":"13.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"391"},{"groupId":"OG001","value":"389"},{"groupId":"OG002","value":"388"}],"units":"Participants"}],"description":"Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Docetaxel (TXT) 75 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG000","title":"Docetaxel 75 mg/m^2"},{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG001","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.","id":"OG002","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)","title":"Time to Tumor Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}